For the 4 patients that experienced clinical benefit with PFS > 6 months, the tumor types were ampullary, colon, pancreatic, and ovarian and only 1 of 4 patients (ovarian) had a mutation identified in an HRD gene (BRCA2; Supplementary Table S1). This evidence concerns the gene BRCA2 and neoplasm.